Why this top broker has upgraded Inghams shares to 'Buy'

Goldman Sachs has upgraded Inghams Group Ltd (ASX: ING) shares to a 'Buy' rating with a 12 month price target of $4.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Goldman Sachs has upgraded Inghams Group Ltd (ASX: ING) to a 'Buy' rating with a 12-month price target of $4. Inghams shares are currently trading at $3.38. Goldman Sachs says Inghams has an attractive valuation with a pending earnings recovery in FY21. 

According to the brokerage, there is an increased likelihood of lower input costs for Inghams over the next 12 months. Earnings recovery will also be driven by management working through cost overruns and processing bottlenecks over the next year. 

Inghams operates in a stable duopoly in Australia and New Zealand and, according to Goldman Sachs, is trading at a 25% discount to its food and agriculture peers. Goldman Sachs expects new management to extract operating efficiency over time and believes this will become evident in second half earnings. 

Despite the ongoing drought in Eastern Australia, recent rains mean there is a better chance of a large winter grain crop which would lower Inghams' input costs. Goldman Sachs estimates a 10% decline in feed costs would increase earnings per share by +4%. 

Capital expenditure is expected to be higher in the short term, however Goldman Sachs is confident Inghams can deliver a return above the weighted average cost of capital. New hatcheries will reduce bottlenecks as demand grows. 

Inghams has forecast second half earnings before interest, tax, depreciation and amortisation (EBITDA) to be above those of the first half and for FY21 to grow on FY20. For the first half, Inghams reported earnings in line with expectations with EBITDA of $91.7 million. 

Underlying net profit after tax declined 24.2% in the first half, resulting in a decline in earnings per share. The dividend was cut 19% in line with this drop, with a 7.3 cents per share dividend declared.

Key risks are centred on higher feed costs, which represent a significant proportion of Inghams costs.  An inability to negotiate high prices with key customers to offset higher costs is also a risk, with Inghams counting the large supermarkets as customers. Customer concentration remains a risk, as do adverse changes in the terms and conditions of contracts with major customers, which could include lower volumes or unfavourable price movements. 

Increases in competition and irrational market behaviour by key competitors could eat into margins, as could further operational issues and equipment efficiency. Biosecurity and food safety issues also represent a risk. 

Foolish takeaway 

Inghams has struggled with operational bottlenecks and inefficiencies, however Goldman Sachs is predicting these will improve. If so, earnings and profits should also rise. 

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A senior couple sets at a table looking at documents as a professional looking woman sits alongside them as if giving retirement and investing advice.
Share Market News

Nickel Industries posts Q4 earnings and lifts outlook

Nickel Industries reports lower December quarter EBITDA.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Market News

Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028

Neuren Pharmaceuticals has projected DAYBUE global net sales to hit US$700 million by 2028.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Why Bell Potter just upgraded this ASX All Ords share to a buy rating

The broker has turned bullish on this growing company. Here's what you need to know.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Bell Potter says these ASX shares are best buys in January

The broker has good things to say about these shares.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Share Market News

Should I invest $1,000 in the VGS ETF?

With $1,000 to invest, diversification matters. This Vanguard ETF provides instant exposure to global markets outside Australia.

Read more »

Close up of a sad young woman reading about declining share price on her phone.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

ASX board.
Best Shares

The best and worst ASX sectors of the past 12 months

A wide gap opened between the best and worst ASX sectors over the past 12 months.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Market News

5 things to watch on the ASX 200 on Monday

A soft start to the week is expected for Aussie investors.

Read more »